Assessing Drug Delivery Systems
Venue: Crowne Plaza
|Event Date/Time: Mar 20, 2006||End Date/Time: Mar 21, 2006|
Drug delivery is a complex task. Poorly soluble compounds represent an estimated 60% of compounds in development and many major marketed drugs. Solubility issues complicating the delivery of new drugs also affect the delivery of many existing drugs.
Experts from leading Pharma & Biotech companies will present, discuss and examine the different types of drug delivery systems and provide you with the insight into emerging or advanced drug delivery approaches that they use.
Uncover best practice strategies to enhance drug solubility and permeability and network with about 60 decision makers from companies representing the drug delivery field of nowadays, as the ability to deliver poorly soluble drugs grows and will grow in significance in the coming years.
Peter Hoffmann, Vice President New Technology Development, Genzyme Corp.
Joerg Breitenbach, Director & Head, Drug Delivery Business (SOLIQS), Abbott Laboratories
Tim Seiffert, Head of Drug Substance Analysis and Smart Chemistry Support, Schwarz Pharma
Richard Green, Associate Research Fellow, Pfizer Global R&D
Main principles of drug solubility, dissolution, permeability and their influence on absorption
Diabetes from drug delivery point of view – assessing drug delivery systems
NanoCrystal Technology for poorly water soluble drugs
Drug delivery as a method of Life Cycle Management
Who should attend:
Vice Presidents, Heads, Senior Level Directors and Managers working in: R&D, Pharmaceutical Development, Formulation & Pre-formulation, Analytical Sciences, Physical Chemistry, Business Development, Drug Delivery, Discovery Support, New Technologies